GeneDx reported Q4 2025 revenue of USD 121 million and adjusted net income of USD 4.4 million, with adjusted gross margin of 71%. Exome and genome test result volume rose 34.3% in Q4 2025 to 27,761, while exome and genome revenue increased 32% year over year (42% excluding a 2024 one-time benefit). Cash on hand was USD 172 million. For FY 2025, GeneDx posted revenue of USD 427.5 million and adjusted net income of USD 41.8 million, with adjusted gross margin of 71%. Exome and genome revenue grew 54% year over year (58% excluding a 2024 one-time benefit), and exome and genome volume increased 30.5%. The company issued FY 2026 guidance for revenue of USD 540 million to USD 555 million, exome and genome revenue growth of 33% to 35%, exome and genome volume growth of 33% to 35%, adjusted gross margin of at least 70%, and positive adjusted net income. Business highlights included continued scaling of the GeneDx Infinity dataset to about 1 million exomes and genomes, expanding payer access with GeneDx contracted with 80% of covered lives, and growth in Medicaid coverage with 38 states covering exome or genome testing and 17 states covering rapid genome sequencing. GeneDx also outlined commercial expansion efforts, including NICU momentum (42 of the top 50 NICUs ordered rapid testing in 2025) and planned ramp in new markets such as general pediatrics, prenatal, and adult specialists in H2 2026, alongside international expansion initiated in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief on February 22, 2026, and is solely responsible for the information contained therein.